Progression of Hip Dysplasia in Mucopolysaccharidosis Type I Hurler After Successful Hematopoietic Stem Cell Transplantation.

@article{Langereis2016ProgressionOH,
  title={Progression of Hip Dysplasia in Mucopolysaccharidosis Type I Hurler After Successful Hematopoietic Stem Cell Transplantation.},
  author={Eveline J. Langereis and Matthijs M den Os and Catherine Mary Breen and Simon A. Jones and O.C. Knaven and Jean Mercer and Weston P Miller and Paula Marie Kelly and Jim F Kennedy and Tyler G Ketterl and Anne O’Meara and Paul J. Orchard and Troy C Lund and Rick Robert van Rijn and Ralph J. B. Sakkers and Klane K White and F. A. Wijburg},
  journal={The Journal of bone and joint surgery. American volume},
  year={2016},
  volume={98 5},
  pages={
          386-95
        }
}
BACKGROUND Dysostosis multiplex contributes substantially to morbidity in patients with Hurler syndrome (mucopolysaccharidosis type I Hurler phenotype [MPS I-H]), even after successful hematopoietic stem cell transplantation (HSCT). One of the hallmarks of dysostosis multiplex in MPS I-H is hip dysplasia, which often requires surgical intervention. We sought to describe in detail the course of hip dysplasia in this group of patients, as assessed by radiographic analysis, and to identify… 

Figures and Tables from this paper

Open issues in Mucopolysaccharidosis type I-Hurler

TLDR
This review will focus on all critical issues related to the management of MPS I-H, including a prolonged neuropsychological follow-up of post-transplant cognitive development of children and residual disease burden.

The Hip in Mucopolysaccharidoses

  • K. Walker
  • Medicine, Biology
    The Pediatric and Adolescent Hip
  • 2019
TLDR
The role of early hip reconstructive surgery still requires further study to determine its efficacy and impact on future hip function and quality of life, as well as Enzyme Replacement Therapy in other MPS conditions.

Long-term effect of hematopoietic cell transplantation on systemic inflammation in patients with mucopolysaccharidoses.

TLDR
Markers related to bone homeostasis remain elevated up to 10 years after HCT and possibly reflect the ongoing skeletal disease, making them potential biomarkers for the evaluation of new therapies.

Treatment of thoracolumbar kyphosis in patients with mucopolysaccharidosis type I: results of an international consensus procedure

TLDR
An international consensus procedure resulted in the first clinical practice guideline for the management of thoracolumbar kyphosis in MPS I patients, focusing on the goals and timing of surgery, as well as the optimal surgical approach, the utility of bracing and required additional assessments.

MPS I: Early diagnosis, bone disease and treatment, where are we now?

TLDR
This article is a state of the art that comprehensively discusses three of the most urgent open issues in MPS I: early diagnosis of Mps I patients, pathophysiological mechanisms behind bone disease, and emerging therapeutic strategies for M PS I bone disease.

Improving diagnosis and treatment outcomes in mucopolysaccharidoses

TLDR
Combined ERT and HSCT in MPS I has clinical utility for selected high-risk individuals, though patients are known to develop anti-drug antibodies, and the efficacy of a non-depleting anti-CD4 monoclonal antibody should be investigated in humans.

Long-term effect of hematopoietic cell transplantation on systemic in fl ammation in patients with mucopolysaccharidoses

TLDR
Systemic in fl ammation is present in untreated MPS patients and is reduced upon treatment with HCT, making them potential biomarkers for the evaluation of new therapies.

Radiographic findings of mucopolysaccharidosis and comparison with bone mineral density: A study from Southeastern Turkey.

  • E. AyazA.E. Bozaci
  • Medicine
    Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
  • 2022

References

SHOWING 1-10 OF 37 REFERENCES

Treatment of hip dysplasia in patients with mucopolysaccharidosis type I after hematopoietic stem cell transplantation: results of an international consensus procedure

TLDR
An international Delphi consensus procedure was initiated to construct consensus-based clinical practice guidelines for hip dysplasia in transplanted MPS I-H patients, and concluded that early corrective surgery for MPS-I patients with hip Dysplasia should be considered.

Hip Dysplasia in Patients With Hurler Syndrome (Mucopolysaccharidosis Type 1H)

TLDR
It is recommended that annual orthopaedic evaluation of hips in patients with HS after HCT and intervention with reconstructive femoral and pelvic osteotomies for their hip dysplasia is recommended.

Prevalence and development of orthopaedic symptoms in the dutch hurler patient population after haematopoietic stem cell transplantation.

TLDR
Dysostosis remains a major problem after haematopoietic stem cell transplantation in Hurler patients, and except for dens hypoplasia, it appears to be progressive and therefore surgical interventions may be necessary in the majority of these patients.

Mobility in Hurler Syndrome

TLDR
Clinically, all patients were independently mobile, with restriction of internal hip rotation being the most significant clinical finding, and ongoing review will clarify the progression of musculoskeletal problems and determine the effectiveness of orthopaedic intervention.

Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study.

Mucopolysaccharidosis type I-Hurler syndrome (MPS-IH) is a lysosomal storage disease characterized by multisystem morbidity and death in early childhood. Although hematopoietic cell transplantation

Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation

TLDR
Investigation of growth in patients with MPS IH after HSCT found children who had no TBI exposure and were younger at the time of HSCT had a better height outcome, and short stature was positively associated with increased age at HSCT.

Characterization of Hip Morphology in Children With Mucopolysaccharidosis Types I and II

TLDR
Hip morphology is variable in MPS I and MPS II ranging from almost normal to severely dysplastic, but some hips do not deteriorate with time and thus surgical intervention may not be necessary in all cases.

Orthopaedic aspects of mucopolysaccharidoses.

TLDR
All patients with MPS should be considered at high risk for surgical intervention requiring anaesthesia because of airway and cardiac disease manifestations, and regular imaging of the cervical, thoracic and lumbar spine, the hips and the lower extremities is recommended.

Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure

TLDR
A European consensus procedure to reach consensus about the use of hematopoietic stem cell transplantation and enzyme replacement therapy for MPS I yielded consensus on the main issues related to therapeutic choices and research.

Hip dysplasia in Hurler's syndrome: orthopaedic management after bone marrow transplantation.

TLDR
The features of hip dysplasia are described in a series of eight successfully engrafted patients with Hurler's syndrome, and the primary pathologic condition appears to be a failure of ossification of the cartilaginous acetabulum.